Molecular Profiling of Clinical Specimens

临床样本的分子分析

• 批准号: 8350129
• 负责人: Daniel Edelman
• 金额: $ 174.77万
• 依托单位: DIVISION OF BASIC SCIENCES - NCI
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/8350129
• 关键词: Adolescent; Adult; Adverse effects; BAY 54-9085; Bioinformatics; Biological Assay; Biological Markers; Biology; Biopsy; Bortezomib; Child; Childhood; China; Clinical; Clinical Investigator; Clinical Trials; Collaborations; Collection; Combined Modality Therapy; DNA Sequence; DNA analysis; Data; Dermatology; Disease; Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor; Erlotinib; Esophageal carcinoma; Evaluation; Follicular Lymphoma; Follow-Up Studies; Gene Expression Profiling; Genome; Genomics; Glioma; Hairy Cell Leukemia; Human; Human Resources; Immunotoxins; Inherited; Investigation; Laboratories; Laboratory Study; Malignant - descriptor; Malignant Neoplasms; Malignant neoplasm of gastrointestinal tract; Malignant neoplasm of lung; Malignant neoplasm of prostate; Medical Oncology; Medicine; Messenger RNA; Metabolism; Methylation; MicroRNAs; Microarray Analysis; Molecular; Molecular Profiling; Molecular Target; NCI Center for Cancer Research; National Cancer Institute; Non-Small-Cell Lung Carcinoma; Outcome; Pathology; Patients; Pediatric Oncology; Performance; Phase; Phase I Clinical Trials; Phase I/II Trial; Phase II Clinical Trials; Phototoxicity; Platinum; Pontine structure; Property; Proteasome Inhibitor; Proteins; Proto-Oncogene Proteins c-akt; RNA; Radiation; Radiation Oncology; Radiation therapy; Recurrence; Refractory; Resistance; Serum; Services; Solid Neoplasm; Specimen; Staging; Stem cell transplant; Technology; Testing; Thymic Carcinoma; Thymoma; Time; Tissue Microarray; Tissue Sample; Triciribine Phosphate; Tumor Biology; Ultraviolet Rays; Unresectable; Urologic Oncology; Ursidae Family; Velcade; Vision; ZD-6474; anticancer research; base; bevacizumab; cancer genome; chemotherapy; chronic graft versus host disease; comparative genomic hybridization; drug testing; epigenomics; inhibitor/antagonist; lapatinib; laser capture microdissection; leukemia; lung small cell carcinoma; mRNA Expression; medullary thyroid carcinoma; melanoma; mutation carrier; next generation; phase 1 study; phase 2 study; pilot trial; programs; protocol development; research clinical testing; tool; tumor; urologic

The Clinical Molecular Profiling Core (CMPC) is a collaborative core that seeks to go beyond the common service paradigm of other cores. The expertise of the personnel allows us to be involved from the start of a project, such as the protocol development, though performance of the assay and biostatistical analysis. Currently, our main function is to support clinical trials at the National Cancer Institute (NCI) and to that end we have collaborations with many of the branches in the Center for Cancer Research (CCR) and the Clinical Center. Over five dozen clinical collaborations have involved many of the branches in CCR such as Medical Oncology, Dermatology, Urologic Oncology, Laboratory of Pathology, Pediatric Oncology, Metabolism, and Radiation Oncology. The status of these collaborations range from preliminary discussions through protocol development, accrual and analysis, and completion. For those that are completed; we look forward to being involved in follow up studies. Many of the studies are clinical trials testing drugs in phase I or II or new combination therapies. These include studies such as Sorafenib and Bevacizumab in Treating Patients With Refractory, Metastatic, or Unresectable Solid Tumors, Pan-HER Inhibitor PF-00299804 in Non-Small Cell Lung Cancer, A Group Wide Biology and Banking Study for Phase II Studies of R1507, Phase II Study of Belinostat in Patients With Recurrent or Metastatic, Unresectable Thymoma or Thymic Carcinoma Previously Treated With Prior Platinum-Containing Chemotherapy, Phase I/II trial of Vandetanib (ZD6474, Zactima) in Children and Adolescents with Hereditary Medullary Thyroid Carcinoma, Identifying Genomic Aberrations in Pediatric Pontine Glioma, a Phase I Study of the AKT inhibitor Triciribine Phosphate Monohydrate and Erlotinib (Tarceva) in Subjects with Advanced Lung Cancer or other Solid Tumors Who are Resistant to or Naive to Epidermal Growth Factor Receptor (EGFR) Inhibitors, a phase II trial in patients with stage IV melanoma for lapatinib treatment when they are ERBB4 mutation carriers, a Targeted Phase I Trial of ZD6474 (Vandetanib; AZCTIMA) plus the Proteasome Inhibitor, Bortezomib (Velcade) in Adults with Solid Tumors with a Focus on Hereditary or Sporadic, Locally Advanced or Metastatic Medullary Thyroid Cancer (MTC), and a Pilot Trial of Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies. However, other investigations are more focused on understanding the underlying pathology of specific diseases and are not directly testing a therapy. These studies include Gene Expression Profiling and Phototoxicity in Adults and Children Exposed to Ultraviolet Radiation, Clinical Evaluations and Laboratory Studies in Patients With Chronic Graft-Versus-Host Disease Who Have Undergone a Stem Cell Transplant, Clinical Manifestations and Molecular Bases of Heritable Urologic Malignant Disorders, Collection of Serum and Tissue Samples From Patients With Biopsy-Proved or Suspected Malignant Disease, Large Scale Methylation Analysis of Follicular Lymphoma, Molecular Profiling of Small Cell Lung Cancer, Molecular Profiling of Thymoma Subsets, Leukemia Biology Study, Esophageal Carcinoma in China, Laser Capture Microdissection and Evaluation of the Microenvironment in Prostate Cancer, Immunotoxin Resistance In Patients With Hairy Cell Leukemia, and Biomarkers and Radiation Side Effects in Patients Undergoing Radiation Therapy for Gastrointestinal Cancer. To support these studies, the CMPC has expertise in many molecular technologies for the analysis of DNA, RNA and protein from human specimens. State of the art assays found on a wide range of advanced platforms include: DNA sequencing (Sanger and next-generation sequencing), mRNA expression analysis (microarray, real-time PCR, bead-based), epigenomic methylation (microarray and pyrosequencing), array comparative genomic hybridization (microarray), and tissue microarrays. Importantly, the CMPC provides full bioinformatics support for all these assays.

临床分子分析核心（CMPC）是一种协作核心，试图超越其他核心的共同服务范式。员工的专业知识使我们可以从项目开始就参与其中，例如协议开发，尽管进行了测定和生物统计分析。目前，我们的主要功能是支持国家癌症研究所（NCI）的临床试验，为此，我们与癌症研究中心（CCR）和临床中心的许多分支机构合作。超过五个临床合作涉及CCR中的许多分支，例如医学肿瘤学，皮肤病学，泌尿科肿瘤学，病理学实验室，儿科肿瘤学，代谢和放射性肿瘤学。这些合作的状态范围从初步讨论到协议开发，应计和分析以及完成。对于那些完成的人；我们期待参与后续研究。许多研究是在I期或II期或新组合疗法中测试药物的临床试验。这些研究包括诸如索拉非尼和贝伐单抗在治疗耐火，转移性或不可切除的固体瘤患者中，在非小细胞肺癌中，在非小细胞肺癌中，pa-herh抑制剂PF-00299804，这是针对R1507的II期研究或II期研究，carcormantation或II期研究的cotartic themant carcormant或cotation carcormant的研究，相互群体的coRCTATIC患者，是相互群体的coRINMS研究先前在先前含铂化学疗法的先前治疗的儿童和青少年对遗传性甲状腺甲状腺癌的儿童和青少年进行了I/II期试验，从（TARCEVA）在患有晚期肺癌或其他实体瘤的受试者中，对表皮生长因子受体（EGFR）抑制剂具有耐药性或天真的抑制剂，这是II期IV期黑色素瘤患者的Lapatinib治疗患者的II期试验，当时是ERBB4突变携带者（ERBB4突变载体），这是一项针对性的IV型eRBB4突变携带者，这是一项靶向I期IV型ZD6474474（Vandetetananib）（Vandetetananib）。 AZCTIMA）加上蛋白酶体抑制剂，硼替佐米（Velcade）的固体肿瘤成年人，重点是遗传或零星，局部晚期或转移性甲状腺甲状腺癌（MTC），以及针对晚期非糖类细胞癌症的分子分析和靶向靶向治疗的小细胞和小细胞癌症，小细胞癌，小细胞癌，小细胞和THIMP。但是，其他研究更专注于理解特定疾病的潜在病理，而不是直接测试治疗。这些研究包括成年人和暴露于紫外线辐射的儿童中的基因表达分析和光毒性，临床评估和实验室研究，患有慢性移植物抗宿主病的患者，患有干细胞移植，临床表现和分子碱基疾病的临床表现和分子碱基疾病，较大的泌尿药物疾病，组织的替代性替代性疾病，替代血液的疾病，替代了较大的乳腺疾病，替代了毒性疾病，或者。卵泡淋巴瘤，小细胞肺癌的分子特征，胸腺胸腺亚群的分子特征，白血病生物学研究，中国的食管癌，激光捕获微分辨率以及对前列腺癌和生物散发性散热性促进性促进性散热性促进性促进性的微调和评估，并评估微型环境，并在毛状细胞中抗性。胃肠癌。为了支持这些研究，CMPC在许多分子技术方面具有专业知识，用于分析人类标本的DNA，RNA和蛋白质。在广泛的高级平台上发现的艺术测定法包括：DNA测序（Sanger和下一代测序），mRNA表达分析（微阵列，实时PCR，基于珠子），表观基因组甲基化（微阵列和PyRosequencing），阵列比较基因组杂交（Microray（Microray）（Microaray（Microray）和组织MicmocroArd Array Arrore。重要的是，CMPC为所有这些测定法提供了全面的生物信息学支持。